12 results about "Salmonella typhosa" patented technology

This invention belongs to the field of molecular biology detection technology, specifically relating to a primer and probe combination for detecting avian Salmonella based on the RAA-LFD method and its application, particularly to a primer and probe combination for detecting three avian serotypes of Salmonella: Salmonella pullorum, Salmonella enteritidis, and Salmonella typhimurium, based on the RAA-LFD method and its application. This invention designs different types of probes and primers targeting the genes of serotypes SP, SE, and STM of Salmonella. Using the primer and probe combination of this invention, rapid, sensitive, and specific detection of Salmonella serotypes and the three avian Salmonella serotypes SP, SE, and STM can be achieved, greatly shortening the detection cycle of avian salmonellosis and improving the detection efficiency and accuracy of avian salmonellosis.

This invention relates to the field of microbial technology, and particularly to a non-lactolytic streptococcus and its application in the preparation of anti-Salmonella infection agents. This invention provides a non-lactolytic streptococcus, wherein the non-lactolytic streptococcus (… Streptococcus alactolyticus The strain was deposited at the China Center for Type Culture Collection (CCTCC) on March 30, 2026, with accession number CCTCC NO: M 2026565. Pre-gavage administration of the described non-lactose-degrading Streptococcus significantly enhanced the host's resistance to Salmonella typhimurium. Host weight loss was slowed after Salmonella typhimurium infection, and the amount of Salmonella typhimurium in the liver and spleen was suppressed, reducing the host's pathogenic load.

The invention relates to the technical field of poultry immunology, in particular to a universal riemerella anatipestifer monoclonal antibody, a detection kit and application of the universal riemerella anatipestifer monoclonal antibody. Specifically, the invention successfully designs the universal riemerella anatipestifer monoclonal antibody, and the detection kit developed based on the monoclonal antibody can rapidly detect the level of the riemerella anatipestifer serum antibody in a sample, and has high sensitivity and strong specificity. The riemerella anatipestifer strain has no cross reactivity with avian enterococcus faecalis, avian salmonella typhimurium, avian escherichia coli and avian salmonella enteritidis, so that the riemerella anatipestifer strain can be applied to rapid screening, epidemiological monitoring and vaccine immune effect evaluation of riemerella anatipestifer infection, and has a wide application prospect.

Disclosed is a method and a device for determining whether a sample contains ampicillin-resistant (AMP-R) non-typhoid Salmonella (NTS). The method comprises detecting, in the sample, the presence of a combination of certain genes or their gene products, wherein the presence of said combination indicates the sample contains AMP-R NTS.

The present application relates to the field of microbial technology, and particularly relates to a broad-spectrum lytic Salmonella sp. phage, a composition and application thereof. The phage is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No. 45281. The phage is isolated from a strain of Salmonella sp., and the core advantage is that (1) it has super-broad-spectrum lytic activity, and can efficiently lyse at least 11 important Salmonella serotypes such as Salmonella enteritidis and Salmonella typhimurium; (2) it has excellent physicochemical stability, and can still maintain high activity after being treated at pH 4-11 and 60 DEG C for 1 hour. Based on the above characteristics, the present application further provides a composition containing the phage, and application thereof in preparing products for food surface disinfection and preservation and prevention and treatment of livestock Salmonella infection. The phage of the present application solves the problems of narrow host spectrum, poor stability and single application scene in the prior art.

The present application relates to the field of microbial technology, and particularly relates to a bacterium El1405 and application thereof in bacteriostasis and anti-inflammation. The bacterium has a preservation number of CGMCC No.31231. The application includes bacteriostasis and anti-inflammation, and the microorganism includes one or more of Listeria monocytogenes, Staphylococcus aureus, Salmonella typhimurium or Escherichia coli. The bacterium can relieve various infection symptoms caused by Salmonella infection, and shows potential in preparation of a drug for treatment and / or prevention of infection of pathogenic bacteria such as Salmonella. The bacterium can also effectively relieve inflammatory bowel disease, reduce intestinal mucosal damage and colon inflammation symptoms, and provide a new strategy for prevention and treatment of inflammatory bowel disease, and has potential clinical application prospect.

This invention discloses the application of *Lactobacillus johnsonii* cell-free supernatant in inhibiting *Salmonella* biofilms, belonging to the field of microbial technology. This invention provides a novel use for *Lactobacillus johnsonii* BNCC186110 cell-free supernatant, which can inhibit the formation of *Salmonella typhimurium* SL1344 and 14028 biofilms, disrupt *Salmonella typhimurium* SL1344 and 14028 biofilms, thereby reducing the colonization of *Salmonella typhimurium* SL1344 and 14028.

This invention relates to the field of avian immunology, and more particularly to a universal monoclonal antibody against Riemerella anatipestifer, a detection kit, and their applications. Specifically, this invention successfully designed a universal monoclonal antibody against Riemerella anatipestifer, and the detection kit developed based on this monoclonal antibody can rapidly detect the level of Riemerella anatipestifer serum antibodies in samples with high sensitivity and strong specificity. Furthermore, it shows no cross-reactivity with Enterococcus faecalis, Salmonella typhi, Escherichia coli, and Salmonella enteritidis, thus it can be used for rapid screening, epidemiological monitoring, and evaluation of vaccine immunization efficacy against Riemerella anatipestifer infection, with broad application prospects.

The invention belongs to the field of biological medicine, and relates to broad-spectrum antibacterial peptide derived from periplaneta americana and anti-tumor application of the broad-spectrum antibacterial peptide. The PA-1 and the PA-2 are both novel alpha-spiral cationic peptides and show remarkable inhibitory activity on pseudomonas aeruginosa, salmonella typhimurium, staphylococcus aureus, staphylococcus epidermidis and carbapenem-resistant acinetobacter baumannii, and the minimum inhibitory concentration on the carbapenem-resistant acinetobacter baumannii reaches 11 [mu] mol / L. In addition, PA-1 and PA-2 can also obviously inhibit the growth of human colon adenocarcinoma cells SW480, cervical cancer cells Hela and gastric cancer cells HGC-27, and show better anti-tumor potential. And the PA-1 and the PA-2 have good thermal stability, pH stability, salt stability and enzyme stability. The two novel active peptides PA-1 and PA-2 provided by the invention show relatively high medicinal values in the antibacterial and anti-tumor fields, and particularly provide a new choice for clinical treatment of carbapenem-resistant acinetobacter baumannii infection.

The invention discloses an application of gallic acid in preparation of a salmonella typhimurium CDSH inhibitor, and belongs to the technical field of biological medicine. CDSH enzyme activity inhibition experiment, H2S detection experiment, antibiotic stimulation experiment and greater wax moth infection model experiment analysis finds that the gallic acid can reduce the stress tolerance of S.Typhimurium by inhibiting the activity of CDSH enzyme, reduce the stress tolerance of S.Typhimurium, reduce the stress tolerance of S.Typhimurium, reduce the stress tolerance of S.Typhimurium, and reduce the stress tolerance of S.Typhimurium by inhibiting the activity of CDSH enzyme. The cysteine thiotransferase has the advantages that the cysteine thiotransferase can be used as a transferase inhibitor, the antibiotic sensitivity and the in-vivo removal effect of the cysteine thiotransferase are enhanced, the gallic acid is used for inhibiting the enzyme activity of CDSH and reducing the salmonella tolerance, and the cysteine thiotransferase inhibitor and the medicine for treating the caused infectious diseases are prepared and are used for preventing or treating salmonella typhimurium infection.

This invention discloses a strain of Bacillus subtilis, its screening method, and its application. The Bacillus subtilis strain is named... Bacillus subtilis BS61, deposited on September 4, 2025, at the China General Microbiological Culture Collection Center (CGMCC), accession number: CGMCC No. 35815. The screening method included phenotypic and genomic screening. Phenotypic screening tested the strain's resistance to acid, bile salts, heat, and artificial gastrointestinal fluids. It revealed that strain BS61 exhibited significantly better antibacterial effects against various pathogens, including *Escherichia coli* K88 and *Salmonella typhimurium*, compared to the standard strain *Bacillus subtilis* BS168. It contains antibacterial secondary metabolic gene clusters such as Fengycin, Thurincin H, and Bacillibactin, but lacks aggressive virulence factors and contains only three low-abundance drug resistance genes. This invention can be applied to the preparation of livestock and poultry feed additives, with no risk of widespread drug resistance. Its use does not affect animal health or food safety, and it can replace antibiotics, improving the intestinal health of livestock and poultry.

The invention is concerning a medical preparation comprising bicyclic heptapeptides for use in vertebrates or humans suffering from an infection caused by Gram-negative bacteria like Pseudomonas aeruginosa, Klebsiella pneumoniae, Acineto-bacter baumannii, Neisseria gonorrhoeae, Chlamydia trachomatis, Shigella sonnei, Salmonella enterica Typhimurium LT2, Enterobacter spp., Bifidobacterium longum, Bacteroides fragilis, Lactobacillus reuteri, Enterococcus spp., Yersinia pestis and numerous other Gram-negative bacteria.